Sanofi
@sanofi
Followers
146K
Following
567
Media
4K
Statuses
7K
An R&D driven, AI-powered biopharma company committed to improving lives and delivering compelling growth. Terms for interactions: https://t.co/mXmuqtkblm
Paris
Joined April 2009
Older adults had the highest rates of flu-related hospitalization compared to the total population in multiple countries, and these were costly. Our #Flunomics report reveals where the protection of older adults needs stronger measures. ➡️ See the data: https://t.co/n0GaBMcIhH
2
4
6
The European Commission has approved our medicine in the EU for certain adults and adolescents with moderate-to-severe chronic spontaneous urticaria (CSU), marking the first targeted treatment option in over a decade. Read more ⬇️ CC: @Regeneron
3
4
10
The @WHO set a flu vaccination coverage target of 75% for older adults. Our #Flunomics report reveals where countries fell short and where better, more tailored approaches to vaccination can protect both people and health systems. 🔗Read more:
2
4
9
At #ACAAI25, we’re presenting phase 3 results in allergic fungal rhinosinusitis (AFRS) in people aged 6 years and older, underscoring our commitment to advancing care for chronic respiratory diseases. CC: @Regeneron
3
3
10
Again and again, we see older adults hospitalized at higher rates than the general population. Our #Flunomics report shows why we shouldn’t underestimate flu each season, and why tailored protection for older adults is key. ➡️
1
4
14
Our Q3 2025 Results are now available. Read the press release. ⬇️ #SanofiResults $SAN $SNY
3
7
11
Results from a phase 2 study evaluating an investigational treatment for alpha-1 antitrypsin deficiency (#AATD), achieved all primary and key secondary endpoints. Read our press release to learn more about our research on this #RareDisease.
1
4
11
#NEWS: The @US_FDA accepted the filing of our sBLA for recently diagnosed stage 3 #Type1Diabetes for expedited review through the FDA Commissioner’s National Priority Voucher (CNPV) pilot program. Learn more ⬇️
1
3
11
We have presented Phase 2 data at #ESMO25 supporting the potential of our investigational therapy for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Read more ⬇️ CC: @OranoMed @RadioMedix
1
3
7
#NEWS: FLUNITY-HD study in @TheLancet assessed the effectiveness of our high-dose #influenza vaccine against hospitalizations in 65+ vs standard-dose. Learn more ⬇️
1
8
18
#NEWS: The @EMA_News CHMP has recommended the approval of our new treatment for adults with immune thrombocytopenia (#ITP), reinforcing our commitment to advance scientific innovation that addresses unmet patient needs in #RareDiseases. Learn more ⬇️
3
2
9
Our Modulus facilities were named as one of @TIME Magazine 2025 Best Inventions in Medical & Healthcare! These next-generation sites in France and Singapore produce multiple vaccines and biologics simultaneously, bringing life-changing treatments to patients faster than ever.
1
3
8
Data from our phase 4 head-to-head study in people with chronic rhinosinusitis with nasal polyps (#CRSwNP) and coexisting asthma has been published in @LancetRespirMed. Learn more about the findings. CC: @Regeneron
1
3
11
The @US_FDA has granted Fast Track designation to our investigational gene therapy for the treatment of #MyotonicDystrophyType 1, reinforcing our dedication to developing new medicines that address unmet needs for people living with #RareDiseases. Learn more ⬇️
0
4
10
The CHMP recommended the approval of our medicine for certain adults and adolescents in the EU with #ChronicSpontaneousUrticaria (CSU), potentially providing a new option for people with this debilitating skin disease. CC: @Regeneron
0
4
9
#NEWS: At #EADVCongress 2025, we’re presenting results from a phase 2a study evaluating our investigational therapy in moderate-to-severe #HidradenitisSuppurativa – a chronic and debilitating inflammatory skin disease. Learn more about our data ⬇️
2
4
18